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Following the publication of a recent meta-analysis by Cipriani et al. (1), various opinion leaders
and news reports claimed that the effectiveness of antidepressants has been definitely proven
(2). E.g., Dr. Pariante, spokesperson for the Royal College of Psychiatrists, stated that this study
“finally puts to bed the controversy on antidepressants, clearly showing that these drugs do
work in lifting mood and helping most people with depression” (https://www.theguardian.com/
science/2018/feb/21/the-drugs-do-work-antidepressants-are-effective-study-shows). We surely
would embrace drug treatments that effectively help most people with depression, but based on
work that has contested the validity of mostly industry-sponsored antidepressant trials (3–6) we
remain skeptical about antidepressants’ clinical benefits. The most recent meta-analysis indeed
concludes that antidepressants are more effective than placebo but also acknowledges that risk of
bias was substantial and that the mean effect size of d = 0.3 was modest (1). Unfortunately, no
clarification is given what this effect size means and whether it can be expected to be clinically
significant in real-world routine practice. In this opinion paper we therefore ponder over how the
reported effect size of d = 0.3 relates to clinical significance and how method bias undermines
its validity, in order that the public, clinicians, and patients can judge for themselves whether
antidepressants clearly work in most people with depression.
STATISTICAL VS. CLINICAL SIGNIFICANCE
Based on statistically significant drug-placebo differences, authors commonly conclude that
antidepressants are effective regardless of the clinical significance of effect sizes. Cipriani et al. (7)
even complained that there was “an undue focus on the binary and polarizing question of clinical
significance” (p. 462). However, statisticians repeatedly cautioned that statistical significance does
not imply practical relevance (8–10). A statistically significant result neither proves that the null
hypothesis is false nor that the alternative hypothesis is true (8, 9, 11). Interpreting a statistically
significant drug-placebo difference as evidence that drugs work is therefore a logical fallacy (12).
The null hypothesis is always false, as a true null-association between natural variables (i.e., d = 0.0)
is nearly impossible due to residual confounding and correlational noise (8, 9). The American
Statistical Association (10) formally states that “A p-value, or statistical significance, does not
measure the size of an effect or the importance of a result” and they further emphasize that
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“Any effect, no matter how tiny, can produce a small p-value if
the sample size or measurement precision is high enough . . . ”
(p. 132). With a total sample size of n = 116,477 as in the most
recent meta-analysis (1), it is therefore not surprising that any
given drug-placebo difference, however small it may be, reaches
statistical significance. Thus, since statistical significance does not
imply clinical significance (10, 12, 13), readers need to consider
what the reported mean effect of d = 0.3 practically means.
As shown in Figure 1, this effect size corresponds to
approximately 2 points on the Hamilton Rating-Scale for
Depression 17-item version (HAMD-17; range 0–52 points),
but per convention a difference <3 points or an effect size
d < 0.5 (corresponding to <4 HAMD-17 points) are considered
clinically irrelevant (14, 15). Research suggests that drug-placebo
differences <3 points are undetectable by clinicians and that
at least 7 HAMD-17 points are necessary for a clinician to
detect a minimal improvement in a patient’s clinical presentation
(16). As a result, the average treatment effect of d = 0.3 must
be considered undetectable and therefore clinically insignificant
in real-world routine practice. Interestingly, a previous meta-
analysis by Jakobsen et al. (14) found comparable effect sizes, but
the authors defined clinical significance a-priori and therefore
questioned the real-world benefits of antidepressants. The effect
sizes reported by Cipriani et al. (1) and Jakobsen et al. (14) are
plotted in Figure 1.
FIGURE 1 | Clinical significance of antidepressants, based on the results of Cipriani et al. (1); additional online information (p. 150) and of Jakobsen et al. (14). Black
squares are the standardized mean differences d (drug vs. placebo) for the most and least effective drug and for the overall effect. Horizontal lines are the related 95%
confidence intervals. Two conventions for clinical insignificance were used. Criterion 1 was a difference of <3 points on the HAMD-17 scale (corresponding to
d < 0.4), and criterion 2 was d < 0.5. Only differences of at least 7 points on the HAMD-17 scale were found to be detectable by clinicians (16). To transform
standardized mean differences into mean point-differences on the HAMD-17 (or vice versa), we assumed a pooled standard deviation of SD = 8.0, as suggested by
Moncrieff and Kirsch (16) and which conforms to data provided in the online appendix by Cipriani et al. (1).
Here we report Cohen’s d effect sizes for the sake of
completeness and because they are often reported in meta-
analyses. However, we emphasize that cut-offs such as d = 0.2
(“small” effect size) or d = 0.5 (“medium” effect size) are
arbitrary and should be interpreted with caution (17). Cohen’s
d is calculated as the mean HAMD-17 difference between
treatment groups divided by their pooled standard deviation.
When samples are homogeneous and inter-individual variability
is low, then the standard deviation is small. All things being
equal, the smaller the standard deviation, the larger Cohen’s d.
E.g., a group difference of 2 HAMD-17 points will yield an effect
size of d = 0.4 when the pooled standard deviation is 5 (2/5 =
0.4), but only an effect size of d = 0.2 when the pooled standard
deviation is 10 (2/10= 0.2). The clinical significance of Cohen’s d
further depends on the outcome. A d= 0.3 referring to mortality
necessarily has more practical relevance than d = 0.3 based on
subjective (and often transient) symptom ratings.
When based on approximately normally-distributed interval
scales, d= 0.3 indicates that, first, the outcome of antidepressants
and placebo overlap by 88%, second, that only 62% of participants
in the antidepressant group score above the mean of the placebo
group and, conversely, 38% score below the mean (referred to as
Cohen’s U3), and, third, that if you pick a person at random from
the antidepressant group, he/she will have a minor chance of
58% to have the better outcome than a person picked at random
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from the placebo group (probability of 50% indicates no benefit
at all) (17). Finally, assuming a placebo response rate of 35–40%
in moderate-to-severe depression (18), based on the Furukawa
formula (19), the number needed to treat (NNT) is approximately
9 [see also (20), who calculated a NNT of 8–10 based on the
results reported by (1)]. This indicates that, relative to placebo,
9 patients need to undergo antidepressant pharmacotherapy for
1 patient to benefit. In consequence, 8 of 9 patients would equally
benefit from an inert placebo pill without risk to eventually suffer
from adverse pharmacologic effects (14, 21) and debilitating
withdrawal symptoms upon discontinuation of drug treatment
(22, 23). A brief synopsis of these findings is that antidepressants
might work in a small minority of patients who do not benefit
from placebo [see also (24)], but for the vast majority an
inert placebo pill that conveys no health risks would work just
as well.
ADDRESSING COMMON OBJECTIONS
A frequently cited paper by Leucht et al. (25) claims that the effect
of antidepressants is comparable to that of other medications in
general medicine, but note that several general medicine drugs
have effect sizes d > 0.8, whereas the effect size of antidepressants
is d= 0.3. Moreover, the general medicine drugs with small effect
sizes reported in Leucht et al. (25) weremostly based on objective,
severe clinical outcomes such as mortality or cardiovascular
events (i.e., “hard” outcomes). Efficacy of antidepressants, in
contrast, is exclusively based on subjective symptom ratings (i.e.,
“soft” outcomes). To provide a fair comparison of the efficacy of
antidepressants and general medicine drugs, researchers should
base the effect size of antidepressants likewise on a severe clinical
outcome such as for instance (fatal) suicide attempts. In that
case the effect size of antidepressants would be close to zero
and favoring placebo (26–30). This compares very unfavorably
to most general medicine drugs.
Another unsubstantiated objection is that the efficacy
of antidepressants is poor due to inadequate psychometric
properties of the HAMD-17 [e.g., its poor content validity (31)].
We do not intend to defend the validity of the HAMD-17, but
instead we want to stress that when the efficacy of antidepressants
relies on other outcome measures, effect sizes are not higher.
First, when efficacy is based on patient self-reports such as the
Beck Depression Inventory (BDI), mean effect sizes are even
smaller (i.e., d < 0.3) than those based on the HAMD-17 (32, 33).
Second, a meta-analysis of all escitalopram trials sponsored by
Forest and Lundbeck, which applied the Montgomery-Asberg
Depression Rating Scale (MADRS), produced a mean effect size
of d = 0.32 (24). Third, there is no evidence from clinical trials
that antidepressants work when efficacy is based on severe clinical
outcomes such as suicide attempts (26–30). I.e., the HAMD-17 is
not accountable for antidepressants’ poor efficacy.
A third objection is that critics of antidepressants unjustifiably
promote psychotherapy although talk therapy is no better than
pharmacotherapy. In response to these concerns we would like
to state that we have also written about the limitations and biases
in psychotherapy research (34). We further agree that in the
short-term (i.e., acute treatment), the outcome of psychotherapy
and pharmacotherapy is comparable (35). Cuijpers and Cristea
(36), two prominent psychotherapy researchers, proposed that
enhanced placebo effects could explain the short-term outcome
of both pharmacotherapy and psychotherapy. Nevertheless, in
the long-term, psychotherapy conveys less physical health risks
and its effect on depression (i.e., sustained remission and
relapse prevention) appears to be superior to pharmacotherapy
according to several meta-analyses of direct comparisons
(37–39).
THE EFFICACY OF ANTIDEPRESSANTS IS
OVERESTIMATED
The average treatment effect detailed above, albeit minor, yet is
most likely an overestimation due to various systematic biases
that inflate the apparent efficacy of antidepressants, including, in
particular, unblinding of outcome assessors (3, 36, 40). Treatment
effects in antidepressant trials are commonly rated by clinicians
who can identify with high accuracy which patients receive the
active drug and which inert placebo based on the reporting, or
a suspicious lack thereof, of recognizable side effects such as
nausea or dry mouth (36, 41). Several lines of evidence suggest
that drug-placebo differences might be inflated when efficacy
estimates are based on subjective symptom rating-scales such as
the HAMD-17.
First, it has consistently been shown that treatment effects
are larger when the outcome is rated by unblinded assessors,
thus efficacy estimates are inflated due to assessors’ treatment
expectancies (42–44). Second, when active placebos that mimic
common antidepressant side effects are applied instead of inert
placebos, the estimated treatment effects are substantially smaller
because assessors are more effectively blinded (45). Third,
antidepressants’ efficacy has been shown to be substantially
smaller when estimates are based on patients’ self-reported
depression symptoms instead of observer-ratings (32, 33),
suggesting that patients do not perceive the same benefit as
(unblinded) clinicians attribute to the drugs. Fourth, with respect
to dropouts due to any reason, which is regarded as an objective
measure of real-world effectiveness (46), antidepressants are, on
average, not superior to placebo (1, 47). Finally, fifth, evidence for
assessor bias was also shown in the most recent meta-analysis,
where antidepressants were judged more efficacious when they
were novel as compared to when they were older (1). Since a
drug does not lose its pharmacologic effect simply because it
has been on the market for a few years, this is evidence for
a systematic overestimation of novel drugs due to clinicians’
treatment expectancies.
Given that the mean drug-placebo difference is only about
2 HAMD-17 points, even a minor bias in symptom-ratings
could fully account for antidepressants’ treatment effect. Indeed,
taking the observer bias into account, Gotzsche (48) calculated
that the effect of antidepressants, relative to placebo, is virtually
zero (OR = 1.02). Note that there are many more systematic
biases than unblinding of outcome assessors that we did not
consider here. These include, for instance, the selective inclusion
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of participants (patients who are known to preferably respond
to the experimental drug are included in the trials, while
none-responders and patients who experienced bothersome
side effects prior to the actual trial are excluded), patient
expectancy bias (patients believe that the drugs work, thus
producing an enhanced placebo response which takes effect as
soon as a patient realizes that he/she receives the active drug),
inadequate management of missing data (the common procedure
of “last observation carried forward” produces inflated efficacy
estimates), and outcome reporting bias (quite often only results
for the most convenient outcome are reported and interpreted)
(3, 49, 50).
CONCLUSIONS
Contrary to the predominant interpretation we contend that
antidepressants do not work in most patients, given that only 1
of 9 people benefit, whereas the remaining 8 are unnecessarily
put at risk of adverse drug effects. To be clear, antidepressants
can have strong mental and physical effects in some patients that
may be considered helpful for some time (51), but there is no
evidence that the drugs can cure depression (3, 40, 48). Insomnia,
fatigue, loss of appetite, psychomotor agitation, and suicidal acts
are recognized depression symptoms (52), but newer-generation
antidepressants may cause precisely these symptoms (14, 29, 46,
53). This is not what we would expect from drugs that effectively
treat depression. Moreover, emerging evidence from well-
controlled long-term pharmacoepidemiologic studies suggests
that antidepressants may increase this risk of serious medical
conditions (21, 54, 55), including dementia (56), stroke (57),
obesity (58), and all-cause mortality (57, 59, 60). Antidepressants
may have clinically meaningful short-term benefits in a small
minority of patients, but the most recent meta-analytic evidence
does not indicate that they work in the majority of patients. A
careful re-evaluation of risks and benefits is therefore needed
before the controversy about the utility of antidepressants can be
put to bed.
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